These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 17786329)
1. Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer. Coelho V; Dernedde J; Petrausch U; Panjideh H; Fuchs H; Menzel C; Dübel S; Keilholz U; Thiel E; Deckert PM Int J Oncol; 2007 Oct; 31(4):951-7. PubMed ID: 17786329 [TBL] [Abstract][Full Text] [Related]
2. Biodistribution and efficacy of [131I]A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer. Panjideh H; Da Silva Coelho VC; Dernedde J; Bachran C; Förster GJ; Franke J; Fasold P; Fuchs H; Thiel E; Deckert PM Int J Oncol; 2008 Apr; 32(4):925-30. PubMed ID: 18360720 [TBL] [Abstract][Full Text] [Related]
3. A33scFv-green fluorescent protein, a recombinant single-chain fusion protein for tumor targeting. Petrausch U; Dernedde J; Coelho V; Panjideh H; Frey D; Fuchs H; Thiel E; Deckert PM Protein Eng Des Sel; 2007 Dec; 20(12):583-90. PubMed ID: 18033820 [TBL] [Abstract][Full Text] [Related]
4. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Chung-Faye GA; Chen MJ; Green NK; Burton A; Anderson D; Mautner V; Searle PF; Kerr DJ Gene Ther; 2001 Oct; 8(20):1547-54. PubMed ID: 11704815 [TBL] [Abstract][Full Text] [Related]
6. 5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells. Lan KH; Shih YS; Chang CA; Yen SH; Lan KL Biochem Biophys Res Commun; 2012 Nov; 428(2):292-7. PubMed ID: 23085230 [TBL] [Abstract][Full Text] [Related]
7. A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy. Deckert PM; Renner C; Cohen LS; Jungbluth A; Ritter G; Bertino JR; Old LJ; Welt S Br J Cancer; 2003 Mar; 88(6):937-9. PubMed ID: 12644833 [TBL] [Abstract][Full Text] [Related]
8. An optimized fermentation process for high-level production of a single-chain Fv antibody fragment in Pichia pastoris. Damasceno LM; Pla I; Chang HJ; Cohen L; Ritter G; Old LJ; Batt CA Protein Expr Purif; 2004 Sep; 37(1):18-26. PubMed ID: 15294276 [TBL] [Abstract][Full Text] [Related]
9. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery. Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688 [TBL] [Abstract][Full Text] [Related]
10. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine. Li JJ; Chang SF; Liau II; Chan PC; Liu RS; Yen SH; Wang HE; Chang CA J Biomed Sci; 2016 Jan; 23():15. PubMed ID: 26801910 [TBL] [Abstract][Full Text] [Related]
11. Genetic construction, expression, and characterization of a single chain anti-CEA antibody fused to cytosine deaminase from yeast. Zamboni S; Mallano A; Flego M; Ascione A; Dupuis ML; Gellini M; Barca S; Cianfriglia M Int J Oncol; 2008 Jun; 32(6):1245-51. PubMed ID: 18497986 [TBL] [Abstract][Full Text] [Related]
12. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). Biela BH; Khawli LA; Hu P; Epstein AL Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121 [TBL] [Abstract][Full Text] [Related]
13. Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine. Deckert PM; Bornmann WG; Ritter G; Williams C; Franke J; Keilholz U; Thiel E; Old LJ; Bertino JR; Welt S Int J Oncol; 2004 May; 24(5):1289-95. PubMed ID: 15067353 [TBL] [Abstract][Full Text] [Related]
14. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein. Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483 [TBL] [Abstract][Full Text] [Related]
16. Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model. You MH; Kim WJ; Shim W; Lee SR; Lee G; Choi S; Kim DY; Kim YM; Kim H; Han SU J Gastroenterol Hepatol; 2009 Aug; 24(8):1393-400. PubMed ID: 19486256 [TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of a human single-chain fragment variable (scFv) antibody against cytosine deaminase from yeast. Mallano A; Zamboni S; Carpinelli G; Santoro F; Flego M; Ascione A; Gellini M; Tombesi M; Podo F; Cianfriglia M BMC Biotechnol; 2008 Sep; 8():68. PubMed ID: 18783590 [TBL] [Abstract][Full Text] [Related]
18. Antitumor therapy mediated by 5-fluorocytosine and a recombinant fusion protein containing TSG-6 hyaluronan binding domain and yeast cytosine deaminase. Park JI; Cao L; Platt VM; Huang Z; Stull RA; Dy EE; Sperinde JJ; Yokoyama JS; Szoka FC Mol Pharm; 2009; 6(3):801-12. PubMed ID: 19265397 [TBL] [Abstract][Full Text] [Related]
19. Targeted tumor therapy with a fusion protein of an antiangiogenic human recombinant scFv and yeast cytosine deaminase. Schellmann N; Panjideh H; Fasold P; Bachran D; Bachran C; Deckert PM; Fuchs H J Immunother; 2012 Sep; 35(7):570-8. PubMed ID: 22892453 [TBL] [Abstract][Full Text] [Related]